NAT MED: China Announces Results of First CRISPR Human Trial
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Existing studies have shown that CRISPR-Cas9 editing immune checkpoint genes can improve the efficacy of T-cell therapy, but we need to understand first about its safety and feasibilityhere, chinese researchers reported the results of the first human Phase I clinical trial of CrispR-Cas9 PD-1-edited T-cells in patients with advanced non-small cell lung cancer (ClinicalTrials.gov NCT02793856)the main endpoint of the experiment was safety and feasibility, and the secondary endpoint was therapeuticExploratory targets include tracking edited T-cellsresults show that all preset endpoints are satisfiedPD-1-edited T-cells are manufactured in vitro through co-transfection of Cas9 and single-stranded guided RNA plasmidsa total of 22 patients were enrolled in the group; 17 had enough edited T-cell infusions, and 12 patients were able to receive treatmentAll treatment-related adverse events are 1/2Edited T-cells can be detected in peripheral blood after infusionThe median progression lifetime was 7.7 weeks (95% confidence interval, 6.9 to 8.5 weeks) and the median total lifetime was 42.6 weeks (95% confidence interval, 10.3 to 74.9 weeks)through next-generation sequencing, the median mutation frequency of 18 candidate sites for non-target events was 0.05% (range, 0-0.25%)therefore, the researchers concluded that the clinical application of CRISPR-Cas9 gene editing T cells was generally safe and feasibleFuture trials should use better gene editing methods to improve efficacy
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
